Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | STAT1 | P42224 | 1/20 | 0.59 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.59 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31476378 | 0.89 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2HTTLMNA | |
| SCHEMBL31476384 | 0.89 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2HTTLMNA | |
| SCHEMBL29029431 | 0.87 | HDAC3 (0.56) | LMNAMAPTMAPK1RXFP1 | |
| SCHEMBL2096261 | 0.85 | TP53 (0.68) | RAB9ANPC1SMN1; SMN2HTTMAPK1 | |
| SCHEMBL5894005 | 0.85 | CA2 (0.52) | RAB9ANPC1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL3892771 | 0.85 | ALDH1A1 (0.52) | RAB9ANPC1SMN1; SMN2HTTLMNA | |
| SCHEMBL296753 | 0.85 | HDAC3 (0.47) | RAB9ANPC1SMN1; SMN2HTTLMNA | |
| SCHEMBL2481722 | 0.85 | HDAC3 (0.47) | RAB9ANPC1SMN1; SMN2HTTLMNA | |
| SCHEMBL999347 | 0.85 | KMT2A (0.61) | RAB9ANPC1SMN1; SMN2HTTLMNA | |
| SCHEMBL296754 | 0.84 | HDAC3 (0.49) | RAB9ANPC1SMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113372243-A | Synthesis process of BOC-3-methoxy-2-methylaniline | 南京爱可德夫科技开发有限公司 | 2021-09-10 | — | — | CN | claimed |
| CN-117447338-B | Lenvatinib intermediate Synthesis method of intermediate | 南昌大学第二附属医院 | 2024-11-15 | — | — | CN | disclosed |
| EP-3919056-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-117447338-A | Synthesis method of lenvatinib intermediate | 南昌大学第二附属医院 | 2024-01-26 | — | — | CN | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-115745958-A | Indole-2-ketone compound and application thereof as bactericide | 中新科农(山东)生态农业有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| CN-113372243-A | Synthesis process of BOC-3-methoxy-2-methylaniline | 南京爱可德夫科技开发有限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-113372243-A | Synthesis process of BOC-3-methoxy-2-methylaniline | 南京爱可德夫科技开发有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-20100173967-A1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | US | disclosed |
| US-20100130487-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-27 | — | — | US | disclosed |
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-20 | — | — | US | disclosed |
| US-7700641-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| CN-101506211-A | Kinase antagonists | UNIV CALIFORNIA (US) | 2009-08-12 | — | — | CN | disclosed |
| US-20080199809-A1 | OPTICAL INFORMATION RECORDING MEDIUM AND METHOD OF RECORDING INFORMATION | FUJIFILM CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080199809-A1 | OPTICAL INFORMATION RECORDING MEDIUM AND METHOD OF RECORDING INFORMATION | FUJIFILM CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | RAB9A 1996/4885NPC1 1520/4885SMN1; SMN2 526/4885 |
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | RAB9A 757/4885NPC1 1791/4885SMN1; SMN2 902/4885 |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | RAB9A 3417/4885NPC1 3777/4885SMN1; SMN2 1176/4885 |
| US-20100130487-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | RAB9A 757/4885NPC1 1791/4885SMN1; SMN2 902/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | RAB9A 3417/4885NPC1 3777/4885SMN1; SMN2 1176/4885 |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | RAB9A 757/4885NPC1 1791/4885SMN1; SMN2 902/4885 |
| US-20100173967-A1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | KLK3, REN, AVPR1B | RAB9A 1571/4885NPC1 244/4885SMN1; SMN2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.